ArticleDysphagia2026
Refining the Protocol and Clinical Pathway for Oesophageal Screening in Videofluoroscopic Swallow Studies: An Examination of Clinical and Operational Impacts Over Five Years.
Article in Dysphagia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
Current international practice guidelines recommend videofluoroscopic swallow studies (VFSSs) include oesophageal screening. However, the clinical application of oesophageal screening is not well established. A multidisciplinary dysphagia team at one hospital refined their oesophageal screening protocol and clinical pathway over five years, exploring clinical and operational impacts. Retrospective chart audits were conducted for 100 consecutive 2024 VFSS patients (refined protocol group). VFSS reports, gastroenterologist (GE) consultations and clinical pathway adherence were compared to previously published VFSS cohorts at the research site (pre-protocol group, 2019-20, n = 100; protocol group, 2020-21, n = 160). There were no differences between the three groups for age (p > .05) or oropharyngeal dysphagia severity (p > .05). Rates of oesophageal screening significantly increased (p < .001) following protocol introduction. In the refined protocol group, there was a significant increase (83% versus 6%, p < .001) in speech-language pathologists (SLPs) providing oesophageal strategy advice and no difference in patient VFSS radiation dose (p > .05) compared to the protocol group when oesophageal screening was conducted. There was no difference between the three groups for new GE consultation rates (p > .05). Post-audit, SLP + GE case discussions were added to the clinical pathway to allow for more individualised management of complex patients. The refined oesophageal screening protocol and clinical pathway expanded clinician understanding of patients' dysphagia by marrying reported symptoms with VFSS findings and led to targeted intervention without adverse impacts. Ongoing work is required to further optimise multidisciplinary dysphagia team collaboration and patient outcomes.
Indexed as
Identifiers
41739168What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.